United States, Food and Drug Administration -- Rules and practice
Resource Information
The concept United States, Food and Drug Administration -- Rules and practice represents the subject, aboutness, idea or notion of resources found in Biddle Law Library - University of Pennsylvania Law School.
The Resource
United States, Food and Drug Administration -- Rules and practice
Resource Information
The concept United States, Food and Drug Administration -- Rules and practice represents the subject, aboutness, idea or notion of resources found in Biddle Law Library - University of Pennsylvania Law School.
- Label
- United States, Food and Drug Administration -- Rules and practice
- Numeration
- Food and Drug Administration
- Subordinate unit
- Food and Drug Administration
40 Items that share the Concept United States, Food and Drug Administration -- Rules and practice
Context
Context of United States, Food and Drug Administration -- Rules and practiceSubject of
No resources found
No enriched resources found
- Unlocking the cures for America's most deadly diseases : hearing before the Subcommittee on Space, Science, and Competitiveness of the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Fourteenth Congress, first session, July 14, 2015
- Allegations of FDA abuses of authority : hearing before the Subcommittee on Oversight and Investigations of the Committee on Commerce, House of Representatives, One Hundred Fourth Congress, first session, July 25, November 15, and December 5, 1995
- An Act to Expand the Tropical Disease Product Priority Review Voucher Program to Encourage Treatments for Zika Virus
- Antitrust concerns and the FDA approval process : hearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, first session, July 27, 2017
- Biosimilar implementation : a progress report from FDA : hearing before the Subcommittee on Primary Health and Retirement Security of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, first session ... September 17, 2015
- Blood supply : FDA oversight and remaining issues of safety : report to the Ranking Minority Member, Committee on Commerce, House of Representatives
- Blood supply : transfusion-associated risks : report to the Ranking Minority Member, Committee on Commerce, House of Representatives
- Dietary Supplement Health and Education Act : is the FDA trying to change the intent of Congress? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, March 25, 1999
- Drug safety : FDA needs to further address shortcomings in its postmarket decision-making process : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Drug safety : further actions needed to improve FDA's postmarket decision-making process : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives
- Drug safety : preliminary findings suggest recent FDA initiatives have potential, but do not fully address weaknesses in its foreign drug inspection program : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Drug safety : preliminary findings suggest weaknesses in FDA's program for inspecting foreign drug manufacturers : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Drug safety: COVID-19 complicates already challenged FDA foreign inspection program : testimony before the Committee on Finance, U.S. Senate
- Examining FDA's Medical Device User Fee Program : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, March 28, 2017
- Examining implementation of the Compounding Quality Act : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, second session, January 30, 2018
- Examining the public health risks of carcinogens in consumer products : hearing before the Subcommittee on Economic and Consumer Policy of the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, March 12, 2019
- Exploring current practices in cosmetic development and safety : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session, on examining exploring current practices in cosmetic development and safety, including S.1014, to amend the Federal Food, Drug, and Cosmetic Act to ensure the safety of cosmetics, September 22, 2016
- FDA user fees 2012 : how innovation helps patients and jobs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, April 18, 2012
- FDA user fees 2012 : issues related to accelerated approval, medical gas, antibiotic development, and downstream pharmaceutical supply chain : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, March 8, 2012
- FDA's mammography inspections : while some problems need attention, facility compliance is growing : report to congressional committees
- Federal oversight of food safety : FDA has provided few details on the resources and strategies needed to implement its Food Protection Plan : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Federal oversight of food safety : FDA's Food Protection Plan proposes positive first steps, but capacity to carry them out is critical : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- How accurate is the FDA's monitoring of supplements like ephedra? : hearing before the Committee on Government Reform, House of Representatives, One Hundred Sixth Congress, first session, May 27, 1999
- Improving animal health : reauthorization of FDA animal drug user fees : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining improving animal health, focusing on reauthorization of Food and Drug Administration animal drug user fees, February 13, 2018
- Keeping small, premium cigar businesses rolling : field hearing before the Committee on Small Business and Entrepreneurship, United States Senate, One Hundred Sixteenth Congress, first session, April 5, 2019
- Medicaid Partnership Act : report together with additional views (to accompany H.R. 5801) (including cost estimate of the Congressional Budget Office)
- Medicaid Pharmaceutical Home Act of 2018 : report together with additional views (to accompany H.R. 5808) (including cost estimate of the Congressional Budget Office)
- Medical device reporting : improvements needed in FDA's system for monitoring problems with approved devices : report to Congressional committees
- Medical devices : European Union's regulatory process
- Medical devices : FDA review times, 1989 through 1996
- Medical devices : challenges for FDA in conducting manufacturer inspections : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives
- Medical devices : protecting patients and promoting innovation : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Twelfth Congress, first session ... November 15, 2011
- Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996
- Options for safe and effective prescription drug importation : hearing before the Committee on Commerce, Science, and Transportation, United States Senate, One Hundred Eighth Congress, second session, March 11, 2004
- Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018 : report together with additional views (to accompany H.R. 5333) (including cost estimate of the Congressional Budget Office)
- Protecting seniors from medication labeling mistakes : hearing before the Special Committee on Aging, United States Senate, One Hundred Thirteenth Congress, first session, Washington, DC, December 11, 2013
- Rare diseases : expediting treatments for patients : hearing before the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining rare diseases, focusing on expediting treatments for patients, October 3, 2018
- Review of the proposed generic drug and biosimilars user fees and further examination of drug shortages : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, February 9, 2012
- The administration's FDA reforms and reduced biopharmaceutical drug prices
- The federal response to the epidemic of e-cigarette use, especially among children, and the Food and Drug Administration's compliance policy : hearing before the Subcommittee on Economic and Consumer Policy of the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, December 4, 2019
Embed
Settings
Select options that apply then copy and paste the RDF/HTML data fragment to include in your application
Embed this data in a secure (HTTPS) page:
Layout options:
Include data citation:
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.law.upenn.edu/resource/dwJ5O_gEV8c/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.law.upenn.edu/resource/dwJ5O_gEV8c/">United States, Food and Drug Administration -- Rules and practice</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.law.upenn.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.law.upenn.edu/">Biddle Law Library - University of Pennsylvania Law School</a></span></span></span></span></div>
Note: Adjust the width and height settings defined in the RDF/HTML code fragment to best match your requirements
Preview
Cite Data - Experimental
Data Citation of the Concept United States, Food and Drug Administration -- Rules and practice
Copy and paste the following RDF/HTML data fragment to cite this resource
<div class="citation" vocab="http://schema.org/"><i class="fa fa-external-link-square fa-fw"></i> Data from <span resource="http://link.law.upenn.edu/resource/dwJ5O_gEV8c/" typeof="CategoryCode http://bibfra.me/vocab/lite/Concept"><span property="name http://bibfra.me/vocab/lite/label"><a href="http://link.law.upenn.edu/resource/dwJ5O_gEV8c/">United States, Food and Drug Administration -- Rules and practice</a></span> - <span property="potentialAction" typeOf="OrganizeAction"><span property="agent" typeof="LibrarySystem http://library.link/vocab/LibrarySystem" resource="http://link.law.upenn.edu/"><span property="name http://bibfra.me/vocab/lite/label"><a property="url" href="http://link.law.upenn.edu/">Biddle Law Library - University of Pennsylvania Law School</a></span></span></span></span></div>
